Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H29N5O6.C2H4O2 |
| Molecular Weight | 507.5368 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CCCCOC(=O)N[C@@H](CNC(=O)C[C@H]1CC(=NO1)C2=CC=C(C=C2)C(N)=N)C(=O)OC
InChI
InChIKey=WDEMHBVIYZGQCD-KALLACGZSA-N
InChI=1S/C21H29N5O6.C2H4O2/c1-3-4-9-31-21(29)25-17(20(28)30-2)12-24-18(27)11-15-10-16(26-32-15)13-5-7-14(8-6-13)19(22)23;1-2(3)4/h5-8,15,17H,3-4,9-12H2,1-2H3,(H3,22,23)(H,24,27)(H,25,29);1H3,(H,3,4)/t15-,17+;/m1./s1
Roxifiban (also known as DMP754), a potent antiplatelet agent in inhibiting platelet aggregation, and has a high specificity and affinity for human platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa) receptors. Roxifiban participated in clinical trials phase III for the treatment of peripheral arterial disorders. This drug was also well tolerated in patients with chronic stable angina pectoris and was studied in the treatment of heparin-induced thrombocytopenia, and thrombosis. However, the development of this drug appears to have been discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates. | 1998 Mar 1 |
|
| Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis. | 2002 Apr |
|
| The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. | 2003 |
|
| [Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor]. | 2017 Nov |
Patents
Sample Use Guides
Ninety-eight patients were randomized to receive either a placebo or 1 of 8 oral dosages of roxifiban. Twenty-two patients were enrolled in multiple-dose regimens, bringing the total study population to 120. The oral dosages were 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, or 2.5 mg/day for up to 30 days.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL18301
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY | |||
|
C104283
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY | |||
|
176022-59-6
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY | |||
|
II-76
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY | |||
|
DTXSID90170069
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY | |||
|
164518
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY | |||
|
0U90EOD13M
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY | |||
|
C152268
Created by
admin on Fri Dec 15 15:45:11 GMT 2023 , Edited by admin on Fri Dec 15 15:45:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
